Nuplazid

Drug ACADIA Pharmaceuticals Inc
Total Payments
$103,852
Transactions
24
Doctors
7
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2021 $1,950 2 2
2020 $1,500 1 1
2019 $45,838 3 0
2018 $29,171 11 0
2017 $25,393 7 4

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $79,633 15 76.7%
Consulting Fee $21,377 6 20.6%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,950 2 1.9%
Travel and Lodging $892.00 1 0.9%

Payments by Type

Research
$79,633
15 transactions
General
$24,219
9 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
ACP-103-055 ACADIA Pharmaceuticals Inc $45,838 0
ACP-103-038 ACADIA Pharmaceuticals Inc $29,171 0
ACP-103-015 ACADIA Pharmaceuticals Inc $4,624 1

Top Doctors Receiving Payments for Nuplazid

Doctor Specialty Location Total Records
Unknown Kansas City, KS $75,009 14
, MD Clinical Neurophysiology Phoenix, AZ $11,000 2
, MD Specialist Carlsbad, CA $6,892 2
, MD Behavioral Neurology & Neuropsychiatry Saint Louis, MO $4,624 1
, MD Neurology Los Angeles, CA $2,877 2
, MD Geriatric Psychiatry Providence, RI $1,500 1
, MD Psychiatry Boston, MA $1,500 1
, M.D Psychiatry Irvine, CA $450.00 1

About Nuplazid

Nuplazid is a drug associated with $103,852 in payments to 7 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is ACADIA Pharmaceuticals Inc.

Payment data is available from 2017 to 2021. In 2021, $1,950 was paid across 2 transactions to 2 doctors.

The most common payment nature for Nuplazid is "Unspecified" ($79,633, 76.7% of total).

Nuplazid is associated with 3 research studies, including "ACP-103-055" ($45,838).